Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.
-
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
-
CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025
-
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
-
CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor
-
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
-
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
-
Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices New investors DaVita Venture Group and Invest-NL join syndicate of international...
-
Corline har tecknat ett utvecklings- och samarbetsavtal med en europeisk leverantör av kärlgrafter för bypassoperationer som används vid kirurgi för patienter med hjärtinfarkt. Avtalet reglerar...